JP2009544618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544618A5 JP2009544618A5 JP2009520862A JP2009520862A JP2009544618A5 JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5 JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aliphatic
- ring
- optionally substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 Chemical compound CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 0.000 description 73
- YMQLSSLCXRWKQA-UHFFFAOYSA-O CC(C(N1)=O)(NC1=O)[IH+] Chemical compound CC(C(N1)=O)(NC1=O)[IH+] YMQLSSLCXRWKQA-UHFFFAOYSA-O 0.000 description 3
- SWFZYGSTUWMTPI-UHFFFAOYSA-N CC(C)(C=CN1)C1=O Chemical compound CC(C)(C=CN1)C1=O SWFZYGSTUWMTPI-UHFFFAOYSA-N 0.000 description 3
- BTJMCRAWBQGQIK-UHFFFAOYSA-N CC(C)(c(ccnc1)c1N1)C1=O Chemical compound CC(C)(c(ccnc1)c1N1)C1=O BTJMCRAWBQGQIK-UHFFFAOYSA-N 0.000 description 3
- FWWMMGOPZBVMNB-UHFFFAOYSA-N CC(C)(c(nccc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(nccc1)c1N1)/C1=[O]\C FWWMMGOPZBVMNB-UHFFFAOYSA-N 0.000 description 3
- CZGJOXNVXIVFAV-UHFFFAOYSA-N CC(C)(c(ncnc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(ncnc1)c1N1)/C1=[O]\C CZGJOXNVXIVFAV-UHFFFAOYSA-N 0.000 description 3
- OISPDNWOHCABMC-UHFFFAOYSA-N CC(C)C(C)(C1C(N2)OCCC1)C2=O Chemical compound CC(C)C(C)(C1C(N2)OCCC1)C2=O OISPDNWOHCABMC-UHFFFAOYSA-N 0.000 description 3
- SHAYFAIWNAOVSE-UHFFFAOYSA-N CC(C)C(C)(c1c(N2)nc[s]1)C2=O Chemical compound CC(C)C(C)(c1c(N2)nc[s]1)C2=O SHAYFAIWNAOVSE-UHFFFAOYSA-N 0.000 description 3
- QGECDFDEEKEVJO-UHFFFAOYSA-N CC(C)C(C)(c1cccnc1N1)C1=O Chemical compound CC(C)C(C)(c1cccnc1N1)C1=O QGECDFDEEKEVJO-UHFFFAOYSA-N 0.000 description 3
- SXVJIQFQZNOJAX-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[IH]C Chemical compound CC(C)C(CC(N1)=O)(C1=O)[IH]C SXVJIQFQZNOJAX-UHFFFAOYSA-N 0.000 description 3
- WWFBWCVOVMKUCZ-UHFFFAOYSA-O CC(C1=C(N2)OCC1)(C2=O)[IH+] Chemical compound CC(C1=C(N2)OCC1)(C2=O)[IH+] WWFBWCVOVMKUCZ-UHFFFAOYSA-O 0.000 description 3
- FHDPJMNNOTUEKT-UHFFFAOYSA-N CC(C1=C(N2)OCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)OCCC1)(C2=O)[IH]I FHDPJMNNOTUEKT-UHFFFAOYSA-N 0.000 description 3
- LVQDZEAOMZKSMI-UHFFFAOYSA-N CC(C1=C(N2)SCC1)(C2=O)I Chemical compound CC(C1=C(N2)SCC1)(C2=O)I LVQDZEAOMZKSMI-UHFFFAOYSA-N 0.000 description 3
- OYOMJOLPSFPIBL-UHFFFAOYSA-N CC(C1C(N2)SCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)SCC1)(C2=O)[IH]C OYOMJOLPSFPIBL-UHFFFAOYSA-N 0.000 description 3
- DQFMPTUTAAIXAN-UHFFFAOYSA-N CC1(C)N=CNC1=O Chemical compound CC1(C)N=CNC1=O DQFMPTUTAAIXAN-UHFFFAOYSA-N 0.000 description 3
- CEDXQSMKYRXVHU-UHFFFAOYSA-N C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C Chemical compound C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C CEDXQSMKYRXVHU-UHFFFAOYSA-N 0.000 description 3
- DFIMFVQCVXMERG-UHFFFAOYSA-N O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 Chemical compound O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 DFIMFVQCVXMERG-UHFFFAOYSA-N 0.000 description 3
- BDEDPOLWMVWPSK-UHFFFAOYSA-N CC(C)(c1c(N2)nc[nH]1)C2=O Chemical compound CC(C)(c1c(N2)nc[nH]1)C2=O BDEDPOLWMVWPSK-UHFFFAOYSA-N 0.000 description 2
- FRUIAUUIOLTTEA-UHFFFAOYSA-N CC(C)(c1c(N2)nc[o]1)C2=O Chemical compound CC(C)(c1c(N2)nc[o]1)C2=O FRUIAUUIOLTTEA-UHFFFAOYSA-N 0.000 description 2
- FMYHJHHHIIJHRN-UHFFFAOYSA-N CC(C)C(C)(c(nccc1)c1N1)C1=O Chemical compound CC(C)C(C)(c(nccc1)c1N1)C1=O FMYHJHHHIIJHRN-UHFFFAOYSA-N 0.000 description 2
- NSEAPTQEZZLMKF-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[I](C)I Chemical compound CC(C)C(CC(N1)=O)(C1=O)[I](C)I NSEAPTQEZZLMKF-UHFFFAOYSA-N 0.000 description 2
- RNWFHTNSACTMTG-UHFFFAOYSA-N CC(C)C1(C(C)I)N=CNC1=O Chemical compound CC(C)C1(C(C)I)N=CNC1=O RNWFHTNSACTMTG-UHFFFAOYSA-N 0.000 description 2
- CYKTWUBYWZXJSX-UHFFFAOYSA-N CC(C1=C(N2)SCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)SCCC1)(C2=O)[IH]I CYKTWUBYWZXJSX-UHFFFAOYSA-N 0.000 description 2
- VHNASZIROAFYSA-UHFFFAOYSA-O CC(C1C(N2)OCC1)(C2=O)[IH+](C)C Chemical compound CC(C1C(N2)OCC1)(C2=O)[IH+](C)C VHNASZIROAFYSA-UHFFFAOYSA-O 0.000 description 2
- LBHWSNRLSIZGPI-UHFFFAOYSA-N CC(C1C(N2)OCCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)OCCC1)(C2=O)[IH]C LBHWSNRLSIZGPI-UHFFFAOYSA-N 0.000 description 2
- VFJSJACITUAVID-UHFFFAOYSA-N CC(C=CN1)(C1=O)[IH]I Chemical compound CC(C=CN1)(C1=O)[IH]I VFJSJACITUAVID-UHFFFAOYSA-N 0.000 description 2
- IJUNQHFGBLBXBB-UHFFFAOYSA-N CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C Chemical compound CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C IJUNQHFGBLBXBB-UHFFFAOYSA-N 0.000 description 2
- BNMHGYUQURKKHB-UHFFFAOYSA-N C[IH]C1=[O][IH]c(ccnc2)c2N1 Chemical compound C[IH]C1=[O][IH]c(ccnc2)c2N1 BNMHGYUQURKKHB-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83239706P | 2006-07-21 | 2006-07-21 | |
| US60/832,397 | 2006-07-21 | ||
| PCT/US2007/016559 WO2008011190A1 (en) | 2006-07-21 | 2007-07-23 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544618A JP2009544618A (ja) | 2009-12-17 |
| JP2009544618A5 true JP2009544618A5 (enExample) | 2011-08-18 |
| JP5511379B2 JP5511379B2 (ja) | 2014-06-04 |
Family
ID=38754729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520862A Expired - Fee Related JP5511379B2 (ja) | 2006-07-21 | 2007-07-23 | Ｃｇｒｐレセプターアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7842686B2 (enExample) |
| EP (1) | EP2049532B1 (enExample) |
| JP (1) | JP5511379B2 (enExample) |
| CN (1) | CN101516875A (enExample) |
| AT (1) | ATE469895T1 (enExample) |
| AU (1) | AU2007275577A1 (enExample) |
| CA (1) | CA2658573A1 (enExample) |
| DE (1) | DE602007006961D1 (enExample) |
| ES (1) | ES2343481T3 (enExample) |
| WO (1) | WO2008011190A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3045182T1 (en) | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| WO2007133491A1 (en) | 2006-05-09 | 2007-11-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| EP2676701B1 (en) | 2008-01-07 | 2016-03-30 | Salutaris Medical Devices, Inc. | Devices for minimally-invasive extraocular delivery of radiation to the posterior portion of the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| MX2010009724A (es) * | 2008-03-04 | 2010-09-28 | Pfizer Ltd | Procedimientos de tratamiento del dolor inflamatorio-. |
| KR101304150B1 (ko) | 2008-03-04 | 2013-09-05 | 라브리스 바이올로직스 인코포레이티드 | 만성 통증의 치료 방법 |
| WO2009120652A2 (en) * | 2008-03-28 | 2009-10-01 | Merck & Co., Inc. | Monocyclic cgrp receptor antagonists |
| EP2331101A4 (en) * | 2008-09-08 | 2012-08-29 | Merck Sharp & Dohme | MONOCYCLIC AMID-CGRP RECEPTOR ANTAGONISTS |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
| EA033109B1 (ru) | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp |
| CN108014334B (zh) | 2011-05-20 | 2021-11-30 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| PT3495392T (pt) | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| LT3552017T (lt) | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| EP3781571B1 (en) | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| GEAP202515803A (en) | 2019-05-02 | 2025-06-10 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
| US20250084044A1 (en) * | 2022-01-14 | 2025-03-13 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4673294B2 (ja) * | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質 |
| US7288559B2 (en) * | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| EP1606264B1 (en) * | 2003-03-14 | 2012-05-02 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirohydantoin cgrp receptor antagonists |
| EP1606286B1 (en) * | 2003-03-14 | 2011-05-11 | Merck Sharp & Dohme Corp. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| AU2004222328B2 (en) * | 2003-03-14 | 2009-10-08 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin CGRP receptor antagonists |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US8003792B2 (en) * | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| AU2005285083B2 (en) * | 2004-09-13 | 2011-03-10 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantoin CGRP receptor antagonists |
| US7659264B2 (en) * | 2004-10-07 | 2010-02-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
-
2007
- 2007-07-23 JP JP2009520862A patent/JP5511379B2/ja not_active Expired - Fee Related
- 2007-07-23 DE DE602007006961T patent/DE602007006961D1/de active Active
- 2007-07-23 CA CA002658573A patent/CA2658573A1/en not_active Abandoned
- 2007-07-23 ES ES07796984T patent/ES2343481T3/es active Active
- 2007-07-23 AU AU2007275577A patent/AU2007275577A1/en not_active Abandoned
- 2007-07-23 WO PCT/US2007/016559 patent/WO2008011190A1/en not_active Ceased
- 2007-07-23 AT AT07796984T patent/ATE469895T1/de not_active IP Right Cessation
- 2007-07-23 EP EP07796984A patent/EP2049532B1/en not_active Not-in-force
- 2007-07-23 CN CNA2007800342187A patent/CN101516875A/zh active Pending
-
2009
- 2009-01-21 US US12/356,745 patent/US7842686B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7664947B2 (ja) | Ｉｌ－１７の調節因子としてのイミダゾリダジン | |
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP7331843B2 (ja) | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 | |
| CA2915561C (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| KR20230026404A (ko) | Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드 | |
| US20220380338A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| AU2018255300A1 (en) | Bicyclic compounds and their use in the treatment of cancer | |
| JP2016516043A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2024519487A (ja) | Ｎａｖ１．８阻害薬としてのアリール ３－オキソピペラジンカルボキサミド類及びヘテロアリール ３－オキソピペラジンカルボキサミド類 | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP7794910B2 (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| BR112020008850A2 (pt) | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 | |
| CA3075669A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| TW200305425A (en) | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient | |
| AU2009298617A1 (en) | Spiro-imidazolone derivatives as glucagon receptor antagonists | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| JP2016513696A5 (enExample) | ||
| CA3149304A1 (en) | Deuterated mk2 pathway inhibitors and methods of using the same | |
| UA128085C2 (uk) | ТРЕТИННІ СПИРТИ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| CA3173777A1 (en) | Inhibitors and degraders of pip4k protein | |
| JP2017538753A5 (enExample) | ||
| CA2948543A1 (en) | Carboxamide derivatives | |
| KR20110044947A (ko) | 과잉활성 면역계 치료를 위한 사이클로리그난의 용도 | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль |